Spots Global Cancer Trial Database for lymphoproliferative disorder
Every month we try and update this database with for lymphoproliferative disorder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma | NCT02057445 | Non-Hodgkins Ly... Hodgkins Lympho... Lymphoprolifera... | EBV CTL's Peripheral Bloo... | 1 Year - | New York Medical College | |
| Project: Every Child for Younger Patients With Cancer | NCT02402244 | Carcinoma In Si... Central Nervous... Childhood Immat... Childhood Lange... Childhood Matur... Congenital Meso... Desmoid Fibroma... Ganglioneuroma Lymphoprolifera... Malignant Solid... Melanocytic Neo... Myeloproliferat... Neuroendocrine ... Stromal Neoplas... | Cytology Specim... Medical Chart R... | - 25 Years | Children's Oncology Group | |
| Project: Every Child for Younger Patients With Cancer | NCT02402244 | Carcinoma In Si... Central Nervous... Childhood Immat... Childhood Lange... Childhood Matur... Congenital Meso... Desmoid Fibroma... Ganglioneuroma Lymphoprolifera... Malignant Solid... Melanocytic Neo... Myeloproliferat... Neuroendocrine ... Stromal Neoplas... | Cytology Specim... Medical Chart R... | - 25 Years | Children's Oncology Group | |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | NCT04883437 | Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent Non-Ho... Lymphoplasmacyt... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L... | Acalabrutinib Obinutuzumab Quality-of-Life... Questionnaire A... | 18 Years - | Emory University | |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | NCT00092222 | Lymphoprolifera... HHV-8 Malignancy HIV | Etoposide Interferon-alph... Rituximab Zidovudine Liposomal Doxor... Bortezomib Valganciclovir Doxorubicin Vincristine Cyclophosphamid... Filgrastim (G-C... Prednisone Sirolimus Observation Onl... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | NCT03258567 | Epstein-Barr Vi... Lymphoma Lymphoprolifera... Disorders, Lymp... | Nivolumab | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Epoetin Alfa in Treating Anemia in Patients With Solid Tumors | NCT00058331 | Anemia Leukemia Lymphoma Lymphoprolifera... Multiple Myelom... Precancerous Co... Unspecified Adu... | epoetin alfa | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | NCT01000753 | Adult Immunobla... Central Nervous... Childhood Immun... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L... Non-Hodgkin Lym... Primary Cutaneo... Primary Cutaneo... Small Lymphocyt... | Cytology Specim... | - 21 Years | Children's Oncology Group | |
| Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | NCT01447056 | Hodgkin Lymphom... Non-Hodgkin Lym... Lymphoprolifera... Nasopharyngeal ... Leiomyosarcoma Severe Chronic ... | LMP specific T ... | - | Baylor College of Medicine | |
| Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma | NCT00093704 | Lymphoma Lymphoprolifera... | bortezomib + ga... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | NCT00092222 | Lymphoprolifera... HHV-8 Malignancy HIV | Etoposide Interferon-alph... Rituximab Zidovudine Liposomal Doxor... Bortezomib Valganciclovir Doxorubicin Vincristine Cyclophosphamid... Filgrastim (G-C... Prednisone Sirolimus Observation Onl... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
